# Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

> **NCT05151471** · PHASE3 · TERMINATED · sponsor: **Tanabe Pharma America, Inc.** · enrollment: 202 (actual)

## Conditions studied

- ALS

## Interventions

- **DRUG:** MT-1186
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05151471
- **Lead sponsor:** Tanabe Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-11
- **Primary completion:** 2023-09-29
- **Final completion:** 2023-09-29
- **Target enrollment:** 202 (ACTUAL)
- **Why stopped:** Futility Analysis of parent study MT-1186-A02 was met.
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05151471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05151471, "Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05151471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*